文献速递眼底病与葡萄膜炎神经眼科

多巴胺增强治疗与新血管性AMD转化风险:目标试验模拟

Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation.
PubMed 文献 · Am J Ophthalmol · 2026-06-23

基于TriNetX美国协作网络电子健康记录,纳入2005年5月至2025年5月诊断为非新血管性AMD的成人,采用目标试验模拟评估左旋多巴±卡比多巴或多巴胺D2受体激动剂是否与降低新血管性AMD转化风险相关。结果显示左旋多巴±卡比多巴组3年转化风险显著低于对照组,而DRD2激动剂组无显著差异。

要点

  • 左旋多巴±卡比多巴与3年新血管性AMD转化风险降低相关。
  • 多巴胺D2受体激动剂与3年转化风险无显著差异。
  • 结果提示多巴胺能信号可能影响AMD进展,需前瞻性研究验证。

核心结论

  • 左旋多巴±卡比多巴使用与较低的3年新血管性AMD转化风险相关,而DRD2激动剂与风险无显著差异。

研究设计与样本

  • 基于人群的临床队列研究,采用目标试验模拟设计。
  • 纳入TriNetX美国协作网络中2005年5月至2025年5月诊断为非新血管性AMD的≥18岁成人。
  • 比较新使用左旋多巴±卡比多巴或DRD2激动剂(普拉克索、罗匹尼罗、溴隐亭、罗替戈汀或卡麦角林)与对照药(泮托拉唑或加巴喷丁)的患者。
  • 采用1:1倾向评分匹配调整人口学、社会因素、合并症和AMD分期。

主要发现

  • 左旋多巴±卡比多巴组相对泮托拉唑组3年转化风险HR为0.67(95%CI 0.45-0.98;左旋多巴n=1312,对照n=1312)。
  • 左旋多巴±卡比多巴组相对加巴喷丁组3年转化风险HR为0.69(95%CI 0.50-0.95;左旋多巴n=1675,对照n=1675)。
  • DRD2激动剂组相对泮托拉唑组3年转化风险HR为0.81(95%CI 0.58-1.13;DRD2 n=1603,对照n=1603)。
  • DRD2激动剂组相对加巴喷丁组3年转化风险HR为0.92(95%CI 0.72-1.19;DRD2 n=2779,对照n=2779)。

关键数值与推荐

  • 主要结局为3年非新血管性AMD向新血管性AMD转化的风险。
  • 使用风险比(HR)及95%置信区间(CI),α水平0.05判定统计学显著性。

临床怎么用

  • 对于非新血管性AMD患者,使用左旋多巴±卡比多巴可能与较低的3年新血管性AMD转化风险相关。
  • 多巴胺D2受体激动剂未显示与新血管性AMD转化风险显著相关。
  • 该发现支持多巴胺能信号可能影响AMD进展,但需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Age-related macular degeneration (AMD) is a leading cause of central vision loss worldwide. Emerging evidence suggests that targeting dopaminergic pathways may influence AMD progression. This study evaluates whether levodopa ± carbidopa or dopamine receptor D2 (DRD2) agonists are associated with reduced risk of conversion to neovascular AMD (nAMD). DESIGN: Population-based clinical cohort study. PARTICIPANTS: Adults aged ≥18 years diagnosed with non-nAMD between May 2005 and May 2025, within the TriNetX US Collaborative Network, a federated electronic health record database spanning 69 healthcare organizations. METHODS: This retrospective cohort study emulated four distinct target trials comparing new users of (1) levodopa (± carbidopa) or (2) DRD2 agonists (pramipexole, ropinirole, bromocriptine, rotigotine, or cabergoline) to new users of two comparators (pantoprazole or gabapentin). Patients with prior nAMD or prescriptions of other dopamine-enhancing agents (eg, selegiline, rasagiline, tolcapone) were excluded. Each exposure group was independently matched to comparators using 1:1 propensity score matching for selected demographics, social factors, comorbidities, and AMD stage. MAIN OUTCOME MEASURES: The primary outcome was 3-year risk of conversion from non-nAMD to nAMD. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. An α level of 0.05 was used to determine statistical significance. RESULTS: Patients prescribed levodopa ± carbidopa had a reduced 3-year risk of conversion to nAMD relative to their matched counterparts prescribed pantoprazole (levodopa n = 1312, control n = 1312; HR 0.67; 95% CI, 0.45-0.98) and gabapentin (levodopa n = 1675, control n = 1675; HR 0.69; 95% CI, 0.50-0.95). No significant difference was observed in 3-year risk of conversion to nAMD between DRD2 agonists use relative to pantoprazole (DRD2 n = 1603, control n = 1603; HR 0.81; 95% CI, 0.58-1.13) or gabapentin (DRD2 n = 2779, control n = 2779; HR 0.92; 95% CI, 0.72-1.19). CONCLUSIONS: In this cohort study, levodopa ± carbidopa use was associated with lower 3-year risk of conversion to nAMD in two independent matched comparisons, whereas DRD2 agonists were not associated with significant differences in risk. These findings suggest dopaminergic signaling may influence AMD progression and warrant further prospective investigation.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Fazal O, Loya A, Muayad J, et al. Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation. Am J Ophthalmol. 2026. PMID: 42336230. doi:10.1016/j.ajo.2026.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。